Ascendis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Eliana Merle from UBS maintained a Buy rating on the stock and has a $307.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eliana Merle’s rating is based on Ascendis Pharma’s strong position in the chronic hypoparathyroidism market, particularly with their product Yorvipath. Despite the recent data release from a competitor, MBX, which showed promising results for their weekly PTH treatment, Merle believes that Ascendis Pharma maintains a leadership position due to Yorvipath’s demonstrated efficacy and time to market advantage.
Merle also highlights the significant market potential for chronic hypoparathyroidism, estimated to be over $10 billion, and sees Ascendis Pharma as well-positioned to capitalize on this opportunity. The anticipated profitability and growth from Yorvipath, along with the upcoming launch of TransConCNP, further support the Buy rating, as these factors suggest a positive trajectory for Ascendis Pharma’s financial performance.
In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $220.00 price target.